Search results for " test"

showing 10 items of 7948 documents

Assessing Human Genetic Variations in Glucose Transporter SLC2A10 and Their Role in Altering Structural and Functional Properties

2018

Purpose: Demand is increasing for clinical genomic sequencing to provide diagnoses for patients presenting phenotypes indicative of genetic diseases, but for whom routine genetic testing failed to yield a diagnosis. DNA-based testing using high-throughput technologies often identifies variants with insufficient evidence to determine whether they are disease-causal or benign, leading to categorization as variants of uncertain significance (VUS). Methods: We used molecular modeling and simulation to generate specific hypotheses for the molecular effects of variants in the human glucose transporter, GLUT10 (SLC2A10). Similar to many disease-relevant membrane proteins, no experimentally derived…

0301 basic medicineMolecular modellcsh:QH426-470Computational biologyBiology03 medical and health scienceschemistry.chemical_compoundGenetic variationmedicinegeneticsnatural variationGenetics (clinical)Genetic testingOriginal Researchmedicine.diagnostic_testmolecular modelingvariant of uncertain significanceGlucose transporterPrecision medicinePhenotypelcsh:Genetics030104 developmental biologychemistryMembrane proteinATSMolecular MedicineDNAFrontiers in Genetics
researchProduct

An siRNA-based screen in C2C12 myoblasts identifies novel genes involved in myogenic differentiation

2017

International audience; AbstractMyogenesis is a highly regulated multi-step process involving myoblast proliferation and differentiation. Although studies over the last decades have identified several factors governing these distinct major phases, many of them are not yet known. In order to identify novel genes, we took advantage of the C2C12 myoblastic line to establish a functional siRNA screen combined with quantitative-imaging analysis of a large amount of differentiated myoblasts. We knocked down 100 preselected mouse genes without a previously characterized role in muscle. Using image analysis, we tracked gene-silencing phenotypes by quantitative assessment of cellular density, myotub…

0301 basic medicineMyoblast proliferationMuscle Fibers SkeletalProliferation[SDV.BC]Life Sciences [q-bio]/Cellular BiologyBiologyMuscle DevelopmentCell LineMyoblastsNovel geneMice03 medical and health sciences0302 clinical medicineRNA interferenceAnimalsMyocyteGenetic TestingRNA Small InterferingGeneCell NucleusGeneticsMyogenesis[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyMyogenesisCell DifferentiationCell BiologyPhenotypeCell biologyPhenotype030104 developmental biologyScreenDifferentiationsiRNARNA InterferenceC2C12C2C12030217 neurology & neurosurgery
researchProduct

Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association f…

2018

Abstract Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic kidney disease (CKD) and negatively affects the prognosis of renal patients. In the last few years, availability of more specific and effective drugs against HCV has dramatically changed the clinical course of this disease. These drugs may provide further advantages in the CKD population as a whole by reducing progression of renal disease, mortality rate and by increasing the survival of graft in renal transplant recipients. The strict …

0301 basic medicineNephrologyDirect-acting antiviral agentmedicine.medical_treatment030232 urology & nephrologyDiseaseHepacivirusurologic and male genital diseasesSeverity of Illness IndexLiver disease0302 clinical medicineRisk FactorsChronic kidney diseasePrevalenceRenal Insufficiency030212 general & internal medicineChronicCooperative BehaviorChronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infection; Antiviral Agents; Cooperative Behavior; Expert Testimony; Hepacivirus; Hepatitis C; Humans; Infectious Disease Medicine; Internal Medicine; Italy; Kidney Transplantation; Nephrology; Renal Insufficiency Chronic; Risk Factors; Severity of Illness Index; Societies; Disease ManagementSocieties MedicalKidney transplantationInfectious Disease Medicineeducation.field_of_studyEvidence-Based MedicineGastroenterologyDisease ManagementHepatitis CGeneral MedicineHepatitis CHCV in renal transplantationHCV infectionInfectious DiseasesTreatment OutcomeChronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infection; Hepatology; GastroenterologyItalyNephrologyEmergency Medicine030211 gastroenterology & hepatologyHemodialysisHumanMicrobiology (medical)medicine.medical_specialtyConsensus030106 microbiologyPopulationConsensuAntiviral AgentsRisk Assessment03 medical and health sciencesRenal DialysisInternal medicineChronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infectionInternal MedicinemedicineHumansRenal Insufficiency ChroniceducationExpert TestimonyAntiviral AgentHepaciviruHepatologybusiness.industryRisk FactorHepatitis C Chronicmedicine.diseaseKidney TransplantationTransplantationDirect-acting antiviral agentsSocietiesbusinessChronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infection; Hepacivirus; Hepatitis C; Humans; Italy; Renal Insufficiency ChronicChronic kidney disease Direct-acting antiviral agents HCV in renal transplantation HCV infection NephrologyKidney disease
researchProduct

In vivo effect of N-ethylmaleimide (NEM) on the measurement of nitrate in plasma

2016

Bioavailability of nitric oxide in the body may be estimated by measuring the concentration of nitrate in plasma. However, it has not been reported whether sequestering of aminothiols in plasma affects the concentration of nitrate in the samples.N-ethylmaleimide (NEM) sequesters aminothiols in plasma therefore we tested the in vivo effect of NEM on the concentration nitrate in plasma.Blood samples were collected from 56 healthy subjects in EDTA vials, EDTA vials containing PBS (pH7.4) and EDTA vials containing NEM dissolved in PBS. Nonparametric statistical tests were used to study the effect of NEM on the concentration of nitrate in plasma measured by the Griess reagent assay and by an HPL…

0301 basic medicineNitratesChromatographyClinical BiochemistryN-EthylmaleimideAnalytical chemistryGeneral Medicine030204 cardiovascular system & hematologyEthylmaleimideHigh-performance liquid chromatographyNitric oxideBioavailability03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicinechemistryNitrateEthylmaleimideGriess testReagentHumansheterocyclic compoundsChromatography High Pressure LiquidClinical Biochemistry
researchProduct

Inherited variants in XRCC2 and the risk of breast cancer

2019

Background XRCC2 participates in homologous recombination and in DNA repair. XRCC2 has been reported to be a breast cancer susceptibility gene and is now included in several breast cancer susceptibility gene panels. Methods We sequenced XRCC2 in 617 Polish women with familial breast cancer and found a founder mutation. We then genotyped 12,617 women with breast cancer and 4599 controls for the XRCC2 founder mutation. Results We identified a recurrent truncating mutation of XRCC2 (c.96delT, p.Phe32fs) in 3 of 617 patients with familial breast cancer who were sequenced. The c.96delT mutation was then detected in 29 of 12,617 unselected breast cancer cases (0.23%) compared to 11 of 4599 cancer…

0301 basic medicineOncologyAdultCancer Researchmedicine.medical_specialtyGenotypeXRCC2DNA repairEpidemiologyBreast NeoplasmsXRCC203 medical and health sciences0302 clinical medicineBreast cancerBreast cancerMutation RateInternal medicinemedicineHumansGenetic TestingAlleleMutation frequencyskin and connective tissue diseasesGeneAllelesGenetic Association StudiesAgedbusiness.industryMiddle Agedmedicine.diseaseDNA-Binding Proteins030104 developmental biologyHereditaryOncology030220 oncology & carcinogenesisMutation (genetic algorithm)MutationFemalePolandbusinessHomologous recombinationBreast Cancer Research and Treatment
researchProduct

Human leukocyte antigen-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute leukemia patients

2017

The immunomodulatory role of human leukocyte antigen (HLA)-E in hematopoietic stem cell transplantation (HSCT) has not been extensively investigated. To this end, we genotyped 509 10/10 HLA unrelated transplant pairs for HLA-E, in order to study the effect of HLA-E as a natural killer (NK)-alloreactivity mediator on HSCT outcome in an acute leukemia (AL) setting. Overall survival (OS), disease free survival (DFS), relapse incidence (RI) and non-relapse mortality (NRM) were set as endpoints. Analysis of our data revealed a significant correlation between HLA-E mismatch and improved HSCT outcome, as shown by both univariate (53% vs. 38%, P=0.002, 5-year OS) and multivariate (hazard ratio (HR)…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentGenotypemedicine.medical_treatment610Hematopoietic stem cell transplantationHuman leukocyte antigen600 Technik Medizin angewandte Wissenschaften::610 Medizin und GesundheitArticle03 medical and health sciencesYoung Adult0302 clinical medicineCell Therapy & ImmunotherapyInternal medicineMedicineHumansTransplantation Homologousddc:610Potassium Channels Inwardly RectifyingSurvival analysisAllelesAgedBone Marrow TransplantationAcute leukemiabusiness.industryDonor selectionHistocompatibility TestingHazard ratioHistocompatibility Antigens Class IHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseasePrognosisSurvival AnalysisTransplantationLeukemiaLeukemia Myeloid Acute030104 developmental biologyTreatment OutcomeImmunologyFemalebusiness030215 immunology
researchProduct

Análisis de biopsias líquidas para el diagnóstico del cáncer: revisión sistemática

2020

The incidence of cancer has increased in recent years, especially in those over 65 years of age, posing a major health problem. Many tumours have a poor prognosis because they are diagnosed at very advanced stages. It is therefore especially important to incorporate liquid biopsy into clinical practice as a method for detecting tumours at very early stages. A systematic review was conducted, with the main objective of analysing the available literature on the use of liquid biopsy in the early diagnosis of cancer, and as a secondary objective, to determine the types of tumours that can be diagnosed early by liquid biopsy and the available biomarkers. The results indicate a lack of agreement …

0301 basic medicineOncologyAgingmedicine.medical_specialtyPoor prognosisScreening testbusiness.industryIncidence (epidemiology)Advanced stageMedicine (miscellaneous)Cancermedicine.diseaseClinical Practice03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisInternal medicinemedicineGeriatrics and GerontologyLiquid biopsybusinessRevista Española de Geriatría y Gerontología
researchProduct

Circulating Molecular Chaperones in Subjects with Amnestic Mild Cognitive Impairment and Alzheimer’s Disease: Data from the Zabùt Aging Project

2022

Molecular chaperones play essential roles in many processes such as cell differentiation, tissue homeostasis, and organ remodeling. Recent data indicate that chaperones can act as cytoprotectants for brain cells during the progression of neurodegenerative diseases, including Alzheimer’s disease (AD). However, very few data on the levels of chaperones in dementia, including its prodromal phases, have been reported. In this study, we used biological samples and epidemiological data collected during the Zabùt Aging Project (a prospective, community-based, cohort study of normal/pathological aging conducted in Sicily, Italy, with a follow-up of ten years) to determine if there is an association…

0301 basic medicineOncologyAgingmedicine.medical_specialtySettore MED/09 - Medicina InternaHsp90DiseaseNeuropsychological Testsmedicine.disease_causeHsp70Cohort Studies03 medical and health sciences0302 clinical medicineAlzheimer DiseaseInternal medicineEpidemiologyoxidative stressHumansMedicineDementiaCognitive DysfunctionProspective StudiesPathologicalTissue homeostasiscognitive impairmentSettore MED/04 - Patologia Generalebusiness.industryGeneral NeuroscienceNeurodegenerationneurodegenerationGeneral Medicinemolecular chaperoneHsp60medicine.diseasePsychiatry and Mental healthClinical Psychology030104 developmental biologySettore MED/26 - NeurologiaGeriatrics and GerontologybusinessAlzheimer’s disease030217 neurology & neurosurgeryOxidative stressMolecular ChaperonesCohort studyJournal of Alzheimer's Disease
researchProduct

Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients

2016

In the last 20 years, following the identification of the BRCA1 and BRCA2 genes (hereinafter referred to as the BRCA genes), preventive pathways have been developed for the identification and clinical management of individuals at high risk of developing breast and ovarian cancer due to the presence of a pathogenic variant in either of these genes. These pathways are aimed at educating high-risk subjects on programs targeted toward early diagnosis and cancer risk reduction. The approval of a novel class of drugs, the PARP enzyme inhibitors, for the treatment of ovarian cancer patients carrying high-risk BRCA pathogenic variants has changed this scenario. BRCA testing, in addition to providin…

0301 basic medicineOncologyCancer ResearchGenes BRCA2Genes BRCA1Brca testingBRCA1; BRCA2; genetic testing; germline mutations; ovarian cancer; PARP inhibitors; somatic mutations; Oncology; Cancer ResearchSettore MED/03 - GENETICA MEDICA0302 clinical medicineClinical decision makingInformed consentsomatic mutationBRCA1 BRCA2 genetic testing germline mutations somatic mutations ovarian cancer PARP inibitorsDisease management (health)PARP inhibitorsOvarian NeoplasmsTumorInformed Consentmedicine.diagnostic_testDisease ManagementGeneral MedicinePrognosisBRCA1; BRCA2; genetic testing; germline mutations; ovarian cancer; PARP inhibitors; somatic mutations; Biomarkers Tumor; Clinical Decision-Making; Disease Management; Female; Genes BRCA1; Genetic Variation; Germ-Line Mutation; Humans; Informed Consent; Mutation; Ovarian Neoplasms; Prognosis; Genes BRCA2; Genetic Testing; Oncology; Cancer Researchovarian cancergermline mutationOncology030220 oncology & carcinogenesisgermline mutationsFemaleHumanmedicine.medical_specialtyPrognosiClinical Decision-MakingMEDLINEgenetic testing03 medical and health sciencesPARP inibitorsInternal medicinemedicineBiomarkers TumorHumansGerm-Line MutationGenetic testingGynecologyBRCA1; BRCA2; PARP inhibitors; genetic testing; germline mutations; ovarian cancer; somatic mutationsbusiness.industryOvarian NeoplasmGenetic Variationmedicine.diseaseBRCA1BRCA2030104 developmental biologyPARP inhibitorGenesMutationsomatic mutationsOvarian cancerbusinessBiomarkers
researchProduct

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

2020

AbstractBackgroundHER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of new therapeutics has led to the approval of pertuzumab combined with trastuzumab and a taxane in first-line, and trastuzumab emtansine (T-DM1) in second-line. Thereby, evidence of T-DM1 efficacy following trastuzumab/pertuzumab combination is limited, with data from some retrospective reports suggesting lower activity. The purpose of the present study is to investigate T-DM1 efficacy in pertuzumab-pretreated and pertuzumab naïve HER2 positive ABC patients. We also aimed to provide evidence on the exposure to d…

0301 basic medicineOncologyCancer ResearchReceptor ErbB-2ApoptosisAdo-Trastuzumab EmtansineSettore MED/06chemistry.chemical_compound0302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsTumor Cells Culturedskin and connective tissue diseasesAged 80 and overMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisGene Expression Regulation NeoplasticSurvival RateOncology030220 oncology & carcinogenesisFemalePertuzumabmedicine.drugT-DM1 efficacymusculoskeletal diseasesAdultmedicine.medical_specialtyHER2+ breast cancer; Trastuzumab/pertuzumab blockade; T-DM1 efficacyBreast NeoplasmsAntibodies Monoclonal Humanizedlcsh:RC254-28203 medical and health sciencesSettore MED/04 - PATOLOGIA GENERALEInternal medicinemedicineBiomarkers TumorHumansneoplasmsAgedCell ProliferationRetrospective StudiesHER2+ breast cancer; T-DM1 efficacy; Trastuzumab/pertuzumab blockadeTaxanebusiness.industryResearchCancerHER2+ breast cancerTrastuzumabmedicine.diseaseTrastuzumab/pertuzumab blockadeBlockadeLog-rank test030104 developmental biologychemistryTrastuzumab emtansineCancer cellbusiness
researchProduct